Table 2.
Cases of retinal detachment following ICI: clinical characteristics and malignancy status.
| Patient No. | Reference | Sex | Age | Malignancy | ICI | Onset | Cancer status | ICI discontinuation | Type of RD |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Current paper | M | 24 | HLRCC | Pembrolizumab | 3 weeks | PR | Yes | ERD |
| 2 | Miyakubo (30) | M | 78 | Melanoma | Ipilimumab | 15 weeks | NR | No | SRD |
| 3 | Wang (31) | F | 64 | RCC | Nivolumab | 12 weeks | NR | No | SRD |
| 4 | Rapisuwon (32) | F | 60 | Melanoma (Uveal) | Ipilimumab + Nivolumab | 4 weeks | Near CR | Continue on nivolumab | SRD |
| 5 | Obata (33) | F | 63 | Melanoma | Nivolumab | 24 days | NR | No | SRD |
| 6 | Telfah (34) | M | 58 | Melanoma | Pembrolizumab | 52 weeks | PR | Yes | ERD |
| 7 | Tsui (35) | M | 60 | Melanoma | Ipilimumab+ Nivolumab | 5 weeks | NR | No | ERD |
| 8 | Theillac (36) | M | 55 | Melanoma | Nivolumab | 4 weeks | NR | Yes | SRD |
| 9 | Crews (37) | M | 46 | Melanoma | Ipilimumab | 6 weeks | NR | Yes | SRD |
| 10 | Mantopoulos (38) | F | 70 | Melanoma | Ipilimumab | 28 weeks | CR | Yes | SRD |
NR, not reported; CR, complete remission; PR, partial remission; RD, retinal detachment; SRD, serous retinal detachment; ERD, exudative retinal detachment; M, male; F, female.